| |
 |
|
Uppsala, Sweden, October 27, 2006
Gyros named as 2006 Entrepreneurial Company of
the Year
Gyros announced today that it has been awarded Frost &
Sullivan’s 2006
Drug Discovery Technologies Entrepreneurial Company of the Year
Award,
just 12 months after receiving the 2005 Excellence in Technology
of the
Year Award, also from Frost & Sullivan. |
| |
| The Entrepreneurial Company of the Year Award is
given to the company that has demonstrated superior entrepreneurial
ability in its industry. The Award signifies the company's identification
of a unique and revolutionary product solution with significant
market potential. In addition, the Award certifies that the company's
marketing strategy is sound and poised for success.
Founded in the year 2000, Gyros has leveraged its core capabilities
in surface chemistries, microfabrication and system integration
to develop a proprietary microfluidics platform for research, drug
discovery/development and biopharmaceutical applications.
The company’s main commercial product, Gyrolab Bioaffy®
CD (compact disc) microlaboratory, is used together with Gyrolab®
Workstation to provide a cost effective and automated solution for
protein quantification at nanoliter scale. Scientists are able to
use immunoassays with a very broad measuring range to generate more
information from less sample, improving throughput and decreasing
costs for labor and reagents.
|
|
Commenting on the award, Jan Würtz, CEO &
President of Gyros AB said; “Everyone in the company has worked
extremely hard to bring our unique technology to a position where
it can really start to make an impact in the development of drugs
and biopharmaceuticals. We have a strong intellectual property position
and are continually exploring collaboration opportunities to expand
our customer base and to develop new applications.”
“The Entrepreneurial Company of the Year award is a welcome
endorsement of our marketing strategy, especially on the back of
last year’s Technology of the Year Award”, added Mr.
Würtz.
Details of
Gyros award (PDF)
|
| |
|
|
|
About Frost & Sullivan Awards
Frost & Sullivan Awards are presented to companies in recognition
of making an outstanding contribution to their respective industry
or achieving a competitive or customer-based leading position in
the market.
What is unique about Frost & Sullivan Awards?
This industry award is unique in that they are presented by a company
dedicated to the analysis and forecasting of high-tech markets since
its inception in 1961. Frost & Sullivan analysts conduct a rigorous
selection methodology unmatched by any other firm.
What is the research methodology utilized in creating this award?
Entrepreneurial ability is assessed using mostly primary research
with top manufacturers and end-users in the industry. Frost &
Sullivan analyst teams perform extensive interviews with the company
in question to evaluate its products, business, and marketing plan.
In addition, primary research with leading manufacturers is performed
to benchmark the award recipient's strategy for growth against established
players' strategies. Also considered are elements such as strategic
alliances, expected time to market, and the senior management team.
Primary research with end-users is also conducted to evaluate and
compare the value of the Award recipient's product solution.
More information about Frost & Sullivan’s Awards Program:
www.awards.frost.com |
| |
|
|
|
About Gyros AB
Gyros is world leader in the miniaturization and integration of
laboratory applications through its proprietary microfluidics platform,
Gyrolab CD (compact disc) microlaboratory. Gyros delivers simple
to use, precisely controlled solutions for processing hundreds of
samples in parallel, generating more information from less sample
and improving lab productivity and efficiency.
Application-specific microlaboratories use a modular design offering
the potential to run different applications on a single instrument
and to create customized solutions. The company is currently focused
on two market segments: quantitative protein analysis for research,
drug discovery and development applications; and, in vitro diagnostics
for medical applications. Gyros has more than 45 employees working
at its headquarters and European sales office in Uppsala, Sweden
and its sales office in the USA.
For further information, visit www.gyros.com
or contact:
Jan Würtz, President and CEO, Gyros AB
Tel: +46 (0)18 566 400
Mobile: +46 (0)70 592 5670
jan.wurtz@gyros.com
------------------------------------------------------------------------------------------------
Statements in this press release that are not strictly historical
may be forward-looking and include risks and uncertainties. Therefore,
though based on Gyros’ current expectations, it should be
duly noted that a variety of factors could cause actual results
and experiences to differ materially from what is herein expressed.
Risks and uncertainties include, but are not limited to, risks associated
with the management of growth and international operations (including
effects of currency fluctuations), variability of operating results,
unforeseen changes in the diagnostic and pharmaceutical markets,
market competition, rapid or unexpected changes in technologies,
fluctuations in product demand, difficulties to successfully develop,
adapt, produce or commercialize products, the ability to identify
and develop new products and to differentiate products from those
of competitors, as well as various legal hazards.
------------------------------------------------------------------------------------------------
|
| |
|
|
| |
|
|
|
